Fig. 4
Forest plots and on ROC analyses. a In univariate analysis, positive CD8, CFRhigh group made a significant contribution to extending PFS in patients with advanced HER2-positive breast cancer, respectively (p = 0.027, HR = 0.162) (p = 0.008, HR = 0.195). b ROC analyses showed that, for advanced HER2-positive breast cancer patients, the results for the CFR (AUC: CFR = 0.708) were better than those for the other factors (AUC: CD8 = 0.681, FOXP3 = 0.639, PD1 = 0.528, PD-L1 = 0.681)